-
Surgery Partners ( NASDAQ: SGRY ) re-affirms its 2022 Adjusted EBITDA guidance of $375M to $385M.
-
2022 revenue expected of $2.50B to $2.55B vs consensus of $2.52B .
For further details see:
Surgery Partners reaffirms FY22 guidanceSurgery Partners ( NASDAQ: SGRY ) re-affirms its 2022 Adjusted EBITDA guidance of $375M to $385M.
2022 revenue expected of $2.50B to $2.55B vs consensus of $2.52B .
For further details see:
Surgery Partners reaffirms FY22 guidanceMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Surgery Partners Inc. Company Name:
SGRY Stock Symbol:
NASDAQ Market:
Surgery Partners Inc. Website:
BRENTWOOD, Tenn., July 16, 2024 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will release its second quarter 2024 results before the market opens on Tuesda...
2024-07-14 11:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-14 15:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...